ArticleLife (Basel, Switzerland)2022
Serum Adropin Levels in Patients with Rheumatoid Arthritis.
Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Decreasing Serum Adropin Levels in Patients With Systemic Lupus Erythematosus: A Case-Control Study.Health science reports · 2026Article
- A Potential Role of Adropin in Inflammatory Rheumatic Diseases-What Do We Know So Far?Biomedicines · 2025Review
- Adropin ameliorates behavioral seizures and the relevant neuroinflammation, oxidative stress, and neural damage in a rat model of pentylenetetrazole-induced seizure potentially by reducing the activation of NF-κB/IkB-α signaling pathway.Metabolic brain disease · 2025Article
- The Role ofInternational journal of molecular sciences · 2025Article
- Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression.Frontiers in endocrinology · 2025Article
- Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases.Frontiers in immunology · 2025Review
- Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin.Frontiers in endocrinology · 2025Article
- Serum adropin level in wet-type age-related macular degeneration.International journal of retina and vitreous · 2024Article
- Serum Adropin Levels and Body Mass Composition in Kidney Transplant Recipients-Are There Sex Differences?Diagnostics (Basel, Switzerland) · 2023Article
- Pathophysiology of Inflammatory Bowel Disease: Innate Immune System.International journal of molecular sciences · 2023Review
- Sex Differences in Adiposity and Cardiovascular Diseases.International journal of molecular sciences · 2022Review
- Adropin's Role in Energy Homeostasis and Metabolic Disorders.International journal of molecular sciences · 2022Review
- Effect of Gamma Rays on Adropin as a Potential Hepatokine Marker for Liver Damage in Male Albino Rats.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adropin is a secretory protein that mainly modulates metabolic homeostasis and endothelial function. There is growing evidence supporting association of adropin with various inflammatory diseases, including rheumatoid arthritis (RA). This study aimed to compare serum adropin levels between 70 patients with RA and 70 matched healthy controls. Furthermore, we explored adropin correlations with RA disease activity, glucose metabolism parameters and inflammatory biomarkers. Serum adropin levels were determined by a competitive enzyme-linked immunosorbent assay. Serum adropin levels were significantly lower in RA patients than in the control group (2.85 ± 0.91 vs. 4.02 ± 0.99 ng/mL,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.